论文部分内容阅读
Objective: To observe the clinical therapeutic effect of Shenmai Injection (SMI) in treating patients of congestive heart failure. Methods: Effect of 16 cases treated with either SMI or potassium magnesium aspartate was observed by randomized crossover method and compared. Results: By using SMI for 2 weeks,the patients’ left ventricular ejective fraction (LVEF) was increased from 29.5±9.0 to 36.6±10.2 ( P <0.05), the heart function of 68.75% patients was improved, no side effect or toxicity was observed. Potassium magnesium aspartate improved the heart function in 37.50% patients only but showed no effect on LVEF. Conclusion: SMI is an effective and safe drug in treating patients with congestive heart failure.
Objective: To observe the clinical therapeutic effect of Shenmai Injection (SMI) in treating patients of congestive heart failure. Methods: Effect of 16 cases treated with either SMI or potassium magnesium aspartate was viewed by randomized crossover method and compared. Results: By using SMI For 2 weeks, the patients’ left ventricular ejective fraction (LVEF) was increased from 29.5±9.0 to 36.6±10.2 (P <0.05), the heart function of 68.75% patients were improved, no side effect or toxicity was observed. Potassium magnesium Aspartate improved the heart function in 37.50% patients only but showed no effect on LVEF. Conclusion: SMI is an effective and safe drug in treating patients with congestive heart failure.